UNASSIGNED: @entity2790 (IOP) promotes the degeneration of @entity2479 cells (RGCs) during the progression of @entity725 ( @entity725 ). However, the molecular mechanisms underpinning IOP-mediated @entity2000 remain unclear. Therefore, by employing a @entity19 model of @entity725 , this study examined whether elevated IOP promotes the @entity2000 by up-regulating tissue plasminogen activator (tPA) and @entity16372 ( @entity16372 ) in the retina. IOP was elevated in @entity19 eyes by injecting fluorescent-microbeads into the anterior chamber. Once a week, for eight weeks, IOP in @entity19 eyes was measured by using Tono-Pen XL. At various time periods after injecting microbeads, proteolytic activity of tPA and @entity16372 in retinal protein extracts was determined by fibrinogen/plasminogen zymography assays. Localization of tPA and @entity16372 , and their receptor @entity20663 ( @entity20663 ) in the retina was determined by immunohistochemistry. RGCs' degeneration was assessed by immunostaining with antibodies against @entity16159 . Injection of microbeads into the anterior chamber led to a progressive elevation in IOP, increased the proteolytic activity of tPA and @entity16372 in the retina, activated plasminogen into plasmin, and promoted a significant @entity2000 . Elevated IOP up-regulated tPA and @entity20663 in RGCs, and @entity16372 in astrocytes. At four weeks after injecting microbeads, @entity20665 ( @entity20665 ; 0.5 and 1.0   M) or tPA-Stop (1.0 and 4.0   M) was injected into the vitreous humor. Treatment of @entity2790 with @entity20665 led to a significant decrease in proteolytic activity of both tPA and @entity16372 , and a significant decrease in IOP-mediated @entity2000 . Also, treatment of @entity2790 with tPA-Stop decreased the proteolytic activity of both tPA and @entity16372 , and, in turn, significantly attenuated IOP-mediated @entity2000 . Results presented in this study provide evidence that elevated IOP promotes the @entity2000 by up-regulating the levels of proteolytically active tPA and @entity16372 .

Tissue and urokinase plasminogen activators instigate the degeneration of @entity2479 cells in a XXXX model of glaucoma.

@entity725 :: ('MESH:C562750', 'Disease') :: ['POAG', 'Primary Open-Angle Glaucoma'] @entity2000 :: ('MESH:D012162', 'Disease') :: ['degeneration of RGCs'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal ganglion'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity16159 :: ('18996(Tax:10090)', 'Gene') :: ['Brn3a'] @entity20665 :: ('16976(Tax:10090)', 'Gene') :: ['receptor associated protein', 'RAP'] @entity2790 :: ('MESH:D009798', 'Disease') :: ['Elevated intraocular pressure', 'IOP-elevated eyes'] @entity20663 :: ('16971(Tax:10090)', 'Gene') :: ['low-density receptor-related protein-1', 'LRP-1'] @entity16372 :: ('18792(Tax:10090)', 'Gene') :: ['urokinase plasminogen activator', 'uPA']
@entity19 :: (10090,Species) :: ['mouse']
